United Therapeutics (UTHR) Net Cash Flow (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Net Cash Flow data on file, last reported at -$277.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 236.85% year-over-year to -$277.4 million; the trailing twelve-month figure through Mar 2026 stood at -$620.2 million (down 195.65% YoY), and the FY2025 full-year result was -$140.1 million, down 128.62% from the prior year.
• Net Cash Flow fell to -$277.4 million in Q1 2026, from $217.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $217.0 million in Q4 2025 to a low of -$306.8 million in Q2 2025.
• A 5-year average of $22.6 million and a median of $43.8 million in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 1885.71% in 2023, while the deepest fall reached 431.49% in 2023.
• Tracing UTHR's Net Cash Flow over 5 years: stood at -$5.6 million in 2022, then surged by 1885.71% to $100.0 million in 2023, then surged by 43.3% to $143.3 million in 2024, then jumped by 51.43% to $217.0 million in 2025, then slumped by 227.83% to -$277.4 million in 2026.
• Business Quant data shows UTHR's Net Cash Flow at -$277.4 million in Q1 2026, $217.0 million in Q4 2025, and -$253.0 million in Q3 2025.